Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given “Buy” Rating at HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $80.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 330.80% from the company’s previous close.

ARWR has been the subject of a number of other research reports. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Citigroup lowered their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 27th. Piper Sandler dropped their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Chardan Capital restated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $43.33.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $18.57 on Wednesday. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -3.70 and a beta of 0.95. The business’s 50-day moving average price is $20.14 and its two-hundred day moving average price is $21.23. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $36.72. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Equities analysts expect that Arrowhead Pharmaceuticals will post -3.4 EPS for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,748 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $21.90, for a total value of $82,081.20. Following the transaction, the director now directly owns 44,125 shares of the company’s stock, valued at $966,337.50. This represents a 7.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the business’s stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. Following the sale, the director now owns 36,740 shares of the company’s stock, valued at approximately $734,800. This represents a 7.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 147,432 shares of company stock valued at $2,957,986 in the last quarter. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ARWR. R Squared Ltd bought a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $38,000. Values First Advisors Inc. acquired a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $52,000. Van ECK Associates Corp increased its position in Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,250 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 788 shares in the last quarter. Finally, KBC Group NV boosted its holdings in Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.